Examining the prevalence and prognosis of cardiac amyloidosis in patients with left ventricular hypertrophy in Turkey

Prevalence and Prognosis of Cardiac Amiloidosis in Turkey- Registry Study

Observational Turkish Society of Cardiology · NCT04915235

This study looks at patients with thickened heart muscles to see how common cardiac amyloidosis is and how it affects their health in Turkey.

Quick facts

Study typeObservational
Enrollment2087 (estimated)
Ages18 Years and up
SexAll
SponsorTurkish Society of Cardiology Academic / other
Locations1 site (Izmir)
Trial IDNCT04915235 on ClinicalTrials.gov

What this trial studies

This observational study focuses on patients diagnosed with left ventricular hypertrophy to determine the prevalence and prognosis of cardiac amyloidosis. An algorithm will be utilized to further assess these patients, particularly those without left ventricular pressure or volume. The study aims to identify cases of cardiac amyloidosis that may otherwise go undetected. By analyzing the data collected, researchers hope to gain insights into the condition's impact on patient outcomes.

Who should consider this trial

Good fit: Ideal candidates include patients with left ventricular hypertrophy who do not have left ventricular pressure or volume issues.

Not a fit: Patients with confirmed sarcometric hypertrophy cardiomyopathy or those with significant left ventricular pressure or volume will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to earlier diagnosis and better management of cardiac amyloidosis in affected patients.

How similar studies have performed: While there may be studies on cardiac amyloidosis, this specific approach focusing on left ventricular hypertrophy in Turkey is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with left ventricular hypertrophy without left ventricular pressure or volume (IVS≥13mm)
* Patients with left ventricular hypertrophy and hypertension or aortic stenosis without left ventricular pressure or volume (IVS\>15mm)

Exclusion Criteria:

* Patients with left ventricular pressure or volume except the ones with aortic stenosis and arterial hypertension
* Patients with sigmoid septum and their hypertrophy limited in sigmoid area
* Patients with highly probable sarcometric hypertrophy cardiomyopathy confirmed with LV morhpology and genetic testing

Where this trial is running

Izmir

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Cardiac Amyloidosis
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.